Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
November 07, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
- Top-line results expected mid 2024 -- Strong physician interest drove SHINE study completion - PURCHASE, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), (the...
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
Phase 2 trials in mild-to-moderate Alzheimer’s disease and dementia with Lewy bodies advancing Clinical site initiation underway in 540-patient early stage Alzheimer’s disease START trial; will...
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer’s Disease at CTAD
October 27, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Christoper van Dyck, M.D., the director of the Yale Alzheimer's Disease Research Unit and the...
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
October 24, 2023 16:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) announced that Willem de Haan, M.D., Ph.D., a neurologist and senior...
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications
October 16, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
Cognition Therapeutics announced presentations from studies of CT1812 at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) conference
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
September 07, 2023 07:45 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its sixth “Conversations” video podcast, which features...
Cognition Therapeutics Announces Participation in Upcoming September Conferences
August 30, 2023 08:00 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
August 08, 2023 07:00 ET
|
Cognition Therapeutics, Inc.
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2 START Trial in Early Alzheimer’s Disease ...
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023
August 02, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by...
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
July 11, 2023 07:30 ET
|
Cognition Therapeutics, Inc.
NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an experimental...